Search Results

November 16, 2016

Phase 3 Study Results Supporting U.S. FDA and European Commission Approvals of STELARA® in the Treatment of Moderately to Severely Active Crohn’s Disease Published in The New England Journal of Medicine

Data from Three Pivotal Phase 3 Studies Detail Efficacy and Safety of First and Only Anti-interleukin-12 and 23 Monoclonal Antibody in Inducing and Maintaining Clinical Response and Remission after One Year of Treatment

Innovative Medicine

November 16, 2016

New Phase 3 Monotherapy Study of Sirukumab Versus Humira® And Sirukumab Data In An Anti-Tnf Refractory Population Reported In The Treatment Of Moderately To Severely Active Rheumatoid Arthritis

Anti-Interleukin-6 Monoclonal Antibody Sirukumab Efficacy and Safety Findings from SIRROUND-H and SIRROUND-T Trials Presented for the First Time at the 2016 ACR/ARHP Annual Meeting

Innovative Medicine

November 15, 2016

Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking Remicade® (Infliximab) Compared To Ct-P13 (Infliximab Biosimilar)

Studies Presented at the 2016 ACR/ARHP Annual Meeting Reveal Higher Discontinuation Rates in Patients Newly Beginning or Switching to Treatment with CT-P13

Innovative Medicine

November 15, 2016

Janssen Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial

Following Positive Phase 3 Results in Moderate to Severe Plaque Psoriasis, Guselkumab Represents the First Specific Anti-Interleukin-23 Monoclonal Antibody to Demonstrate Significant Improvement in Signs and Symptoms of Active Psoriatic Arthritis

Innovative Medicine

November 14, 2016